ELX-02, Potential Therapy for CF Nonsense Mutations, Named Orphan Drug

ELX-02, Potential Therapy for CF Nonsense Mutations, Named Orphan Drug
0
(0)

ELX-02, an investigational treatment of cystic fibrosis due to nonsense mutations, has been designated an orphan drug by the U.S. Food and Drug Administration (FDA).

This designation is given to treatments with the potential to improve care for rare diseases, defined as those affecting fewer than 200,000 people in the U.S. It qualifies its developer, Eloxx Pharmaceuticals, to benefits that include seven years of marketing exclusivity if approved, and financial incentives like waived fees, and tax credits to advance its development and testing.

“We are pleased to have received orphan drug designation from the FDA for ELX-02 in the U.S.,” Gregory Williams, PhD, CEO of Eloxx, said in a press release.

“Combined with our previous EMA orphan medicinal product designation in Europe, and upon approvals in the U.S. and the E.U., we will be able to … provide treatment options to patients with high unmet medical needs, particularly in patients with nonsense mutations for whom there are few, if any, treatments available,” Williams added.

Cystic fibrosis (CF) is caused by mutations in the gene CFTR, resulting in the production of a faulty CFTR protein.

One type of CF-causing mutation is known as a nonsense mutation. These are mutations that cause a “stop” signal to be coded in the gene, somewhat analogous to having a period erroneously placed in the middle of a sentence. A premature stop codon results in the production of a shortened protein that is unable to work properly.

ELX-02 is designed to restore the production of full-length and functional CFTR protein. The therapy works by binding to ribosomes — the cells’s protein-making machinery — allowing them to “read through” the aberrant stop signal to generate fully working protein.

Phase 1 clinical trials conducted in healthy volunteers showed that ELX-02 was generally well tolerated, and preclinical studies have supported its efficacy.

Eloxx is currently sponsoring two Phase 2 clinical trials — called EL-004 (NCT04126473) and EL-012 (NCT04135495) — to test ELX-02 in people with CF who have at least one G542X mutation in CFTR, the most common CF-causing nonsense mutation.

EL-004, taking place in Germany and Israel, aims to enroll 16 patients; EL-012 is being conducted in the U.S. and plans to enroll eight patients. Enrollment for both trials was nearly complete at the start of the year, but both trials were paused due to the COVID-19 pandemic.

Enrollment in EL-004 recently restarted, while EL-012 remains on hold at its five U.S. sites. Contact and site information about EL-004 can be found here; information about EL-012 is here.

“As previously announced, we have resumed enrollment in our Phase 2 proof of concept clinical trials in Israel and Europe, with our trial in the U.S. continuing to be temporarily paused due to the COVID-19 pandemic,” Williams said. “We look forward to reporting top line results as soon as feasible.”

Marisa, a science writer, holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Total Posts: 336

Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.

×
Marisa, a science writer, holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.
Latest Posts
  • BiomX announcement
  • MS1819
  • CF Foundation award
  • pancreatic insufficiency trial

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published. Required fields are marked *